Tonix's long COVID drug fails to meet mid-stage trial goal
Sept 5 (Reuters) - Tonix Pharmaceuticals Holding Corp said on Tuesday its experimental drug failed to meet the primary goal in a mid-stage study for management of widespread muscle pain and tenderness associated with long COVID-19. (Reporting by Leroy Leo in Bengaluru; Editing by Dhanya Ann Thoppil)